This prediction market asks whether the U.S. Department of the Treasury or the Internal Revenue Service (IRS) will announce retroactive relief from Section 280E of the Internal Revenue Code for state-licensed medical marijuana businesses before January 1, 2027. Section 280E, enacted in 1982, prohibits businesses from deducting ordinary business expenses if they traffic in controlled substances (as defined by federal law), including cannabis. Since cannabis remains a Schedule I drug under the Controlled Substances Act, state-licensed medical and recreational cannabis businesses cannot deduct expenses like rent, payroll, or utilities, resulting in effective federal income tax rates that can exceed 70%. This creates a severe financial burden, especially for medical marijuana operators who operate legally under state law but face federal tax penalties. Calls for reform have grown as the cannabis industry has matured. The SAFE Banking Act and the MORE Act have passed the House multiple times but stalled in the Senate. More targeted efforts, like the Small Business Tax Equity Act, would allow medical cannabis businesses to deduct expenses, but they have not become law. In 2023, the Treasury Department and IRS faced public pressure and legal challenges from cannabis businesses arguing that Section 280E violates their constitutional rights by imposing punitive taxes without due process. Some courts have sided with taxpayers in narrow cases, but no broad administrative relief has been granted. In 2024, the U.S. Department of Health and Human Services (HHS) recommended rescheduling cannabis from Schedule I to Schedule III, which would effectively exempt medical cannabis businesses from Section 280E because Schedule III substances are not subject to the provision. The Drug Enforcement Administration (DEA) has not yet acted on this recommendation, and the timeline for rescheduling remains uncertain. If rescheduling occurs, the Treasury and IRS would not need to issue retroactive relief because the underlying law would no longer apply to medical cannabis businesses. However, if rescheduling does not happen or is delayed, pressure on Treasury and the IRS to provide retroactive relief could intensify. People are interested in this market because it directly affects the financial viability of thousands of cannabis businesses, the tax revenues of states with legal cannabis markets, and the broader debate about federal cannabis policy. A Yes outcome would signal a major shift in federal enforcement priorities and could provide immediate financial relief to an industry that paid an estimated $1.8 billion in excess taxes due to Section 280E in 2022 alone. A No outcome would maintain the status quo, keeping cannabis businesses at a competitive disadvantage relative to other industries and potentially driving more operators into the illicit market or bankruptcy.

Historical Context

Section 280E was added to the Internal Revenue Code in 1982 as part of the Tax Equity and Fiscal Responsibility Act (TEFRA). The provision was specifically designed to prevent drug traffickers from deducting business expenses like rent and phone bills, following the high-profile case of a convicted drug dealer who successfully deducted expenses related to his cocaine trafficking business. The law states that no deduction or credit shall be allowed for any amount paid or incurred in carrying on any trade or business that consists of trafficking in controlled substances (as defined by the Controlled Substances Act). When states began legalizing medical cannabis in the 1990s (California's Proposition 215 in 1996) and recreational cannabis in the 2010s (Colorado and Washington in 2012), cannabis businesses faced an unexpected tax burden. The IRS began auditing these businesses aggressively in the late 2000s, applying Section 280E to deny deductions for ordinary business expenses. In 2010, the Tax Court case Californians Helping to Alleviate Medical Problems (CHAMP) v. Commissioner affirmed that Section 280E applies to state-legal medical cannabis dispensaries, rejecting the argument that they were not drug traffickers under federal law because they operated with state authorization. The Cole Memorandum of 2013 (issued by Deputy Attorney General James Cole) provided some enforcement discretion for federal prosecutors but did not affect tax law. The IRS continued to apply Section 280E uniformly. By 2019, the IRS had issued over 100 Chief Counsel Advice memoranda on the topic, consistently denying deductions. In 2021, the House passed the MORE Act, which would have removed cannabis from the Controlled Substances Act entirely, but the Senate did not act. The HHS recommendation to reschedule cannabis to Schedule III in August 2023 marked the first major federal shift on cannabis scheduling in over 50 years. If finalized, this would remove medical cannabis businesses from Section 280E coverage because Schedule III substances are not subject to the provision. However, retroactive relief for prior tax years would require specific administrative action or legislation, as rescheduling only applies prospectively.